Investment
Features
FeesSafety
Academy
More
Pluang+

AngioDynamics shares plunge 21% despite Q1 revenue growth and improved losses

Company Fundamentals
13 Oct 2026
Gordon Thompson
View Source
Bearish
AngioDynamics shares plunge 21% despite Q1 revenue growth and improved losses

AngioDynamics reported a 6.9% revenue increase to $80.9 million and improved adjusted loss to $0.04 per share in Q1 fiscal 2027. The company saw strong growth in Med Tech products and a 4.1% rise in gross margin, yet its stock dropped over 21% on heavy trading volume. Analyst H.C. Wainwright lowered the price target to $18, indicating potential upside from the current $10.77 share price. Additionally, AngioDynamics announced a new CEO, Eric Honroth, starting November 2. Despite positive financial trends, investor reaction was negative, causing a sharp sell-off.

AngioDynamics' recent financial results and leadership change provide context for market activity. For readers following the health sector, here is Pluang's market snapshot as of Oct 14, 2026 20:11 WIB: Among 150 priced health-sector US stocks tradable on Pluang, 73 rose and 68 fell today. Notable movers include ARWR at USD 59.90 with a 1-day change of +3.04% and a typical hold time of 5 days, TXG at USD 70.02 down 2.47% with a typical hold time of 92 days and 100% buy order activity, and CLPT at USD 10.03 up 2.24% with a typical hold time of 10 days and 100% buy order activity.

More News

Genesis Global wins Best AI Solution for Software Development at 2026 AI in Capital Markets Awards

Genesis Global wins Best AI Solution for Software Development at 2026 AI in Capital Markets Awards

Genesis Global won the Best AI Solution for Software Development award at the 2026 AI in Capital Markets Awards for its product Genesis Create. This software combines AI with reusable components and financial expertise to help firms develop productio...

Others
Bullish
1 hour ago
nuVizz named Accelerator in 2026 Nucleus Research TMS Value Matrix for last-mile delivery tech

nuVizz named Accelerator in 2026 Nucleus Research TMS Value Matrix for last-mile delivery tech

nuVizz has been recognized as an Accelerator in the 2026 Nucleus Research Transportation Management Value Matrix for its specialized last-mile delivery technology. The platform excels in coordinating complex delivery networks involving private fleets...

Market News
Bullish
1 hour ago
ASML reports strong Q3 2026 EPS of $14.65 on high chip equipment demand despite slight revenue miss.

ASML reports strong Q3 2026 EPS of $14.65 on high chip equipment demand despite slight revenue miss.

ASML Holding posted a strong Q3 2026 earnings per share of $14.65, beating estimates of $12.17, driven by a 55% year-over-year sales growth and a 57.5% gross margin. Although revenue was slightly below expectations at $13.05 billion, the company bene...

Company Fundamentals
Bullish
2 hours ago
Charles Schwab Q3 earnings expected to rise on strong trading and asset management revenue.

Charles Schwab Q3 earnings expected to rise on strong trading and asset management revenue.

Charles Schwab is set to report its Q3 2026 earnings with an estimated EPS of $1.66 and revenue around $7.18-$7.19 billion, reflecting significant growth driven by an 18.2% increase in trading revenue, net interest income, and asset management fees. ...

Company Fundamentals
Bullish
2 hours ago
TSOs prioritize software investments to boost grid security and capacity amid rising demand

TSOs prioritize software investments to boost grid security and capacity amid rising demand

Transmission System Operators (TSOs) are increasingly investing in software like Energy Management Systems and grid planning tools to modernize aging infrastructure, enhance cybersecurity, and expand grid capacity. Cybersecurity remains their top con...

Market News
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App